GABPA

(redirected from NRF2)

GABPA

A gene on chromosome 21q21.3 that encodes the alpha subunit of the GA-binding protein, which forms a tetrameric complex with two beta subunits and stimulates transcription of target genes. The encoded protein may downregulate cytochrome oxidase expression and may play a role in nuclear control of mitochondrial function.
References in periodicals archive ?
Keywords: Peroxisome proliferator-activated receptor gamma (PPARI3), Nuclear regulatory factor 2 (NRF2), Oxidative stress, Developmental block, Maternal-to-zygotic transition.
Nuclear factor erythroid-related factor 2 (Nrf2) is a transcription factor responsible for the regulation of cellular redox balance and protective antioxidant and phase II detoxification responses in mammals (17,18).
Next, nuclear factor erythroid 2-related factor 2 (Nrf2) was knocked down with Nrf2 small interfering RNA (siRNA) to confirm the specific role of Nrf2 in mucin regulation of CUR in NCI-H292 cells.
LifeVantage will initially offer its complete TrueScience Beauty System - the company's popular line of Nrf2-enhanced skin care products - with its flagship Protandim Nrf2 Synergizer anticipated to follow in the near future.
They have shown for the first time that the transcription factor Nrf2 largely mediates the potentiating effect of plant polyphenols on 1,25D-induced differentiation in human AML cells.
The study focused on the role of two cell signaling pathways--KEAP1/ NRF2 and PI3K-which are known to be involved in adenocarcinomas.
In view of liraglutide's antioxidative stress activity, we speculated that it could activate the nuclear factor erythroid 2-related factor (Nrf2)/heme oxygenase-1 (HO-1) pathway in the treatment of diabetes complicated with cerebral infarction.
Nuclear factor erythroid 2-related factor 2 (Nrf2), a redox-sensitive transcription factor, is bound to the negative regulator Kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm and degraded by the ubiquitin-proteasome pathway in basal condition [11].
Immunohistochemical markers for G6PDH, 6PGL, 6PGDH, and NRF2 were assessed by a semiquantitative evaluation method as follows [15]: 0: negative or weak immunostaining in <1% of the tumor; 1: focal expression in 1-10% of the tumor; 2: positive in 11%-50% of the tumor; and 3: positive in 51%-100% of the tumor.
indicated that the HER2-targeted therapeutic treatment promoted reactive oxygen species (ROS), glutathione (GSH) depletion, reduction in nuclear factor erythroid 2-related factor 2 (Nrf2) levels, and inhibition of Nrf2 function in ovarian cancer cell lines [14].